American journal of hypertensionOct 23, 2025

How GLP-1 Medications Affect Blood Pressure

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jan 2, 2026

Abstract

GLP-1 receptor agonists are associated with modest reductions in blood pressure of 2 to 5 mmHg systolic.

Blood pressure reductions may primarily result from weight loss.
Potential weight-independent mechanisms include improved kidney function, better blood vessel health, and reduced inflammation in blood vessels.
The blood pressure-lowering effects of GLP-1 receptor agonists, while smaller than traditional blood pressure medications, could still contribute to reducing cardiovascular risk on a larger scale.
These medications are generally well tolerated among individuals with high blood pressure, though small increases in heart rate and interactions with certain medications may require monitoring.
Emerging GLP-1 based therapies may enhance understanding and treatment of blood pressure in cardiometabolic care.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the treatment of type 2 diabetes and, more recently, for weight management among individuals without diabetes. Beyond their metabolic effects, growing evidence suggests that GLP-1 RAs produce modest reductions in blood pressure (BP), typically 2 to 5 mmHg systolic, across diverse populations with diabetes, obesity, or at high cardiovascular risk. These reductions appear to be driven primarily by weight loss, with additional contributions from potential weight-independent mechanisms such as natriuresis, improved endothelial function, and attenuation of vascular inflammation. Although smaller in magnitude than those achieved with traditional antihypertensive drugs, the BP-lowering effects of GLP-1 RAs can translate into meaningful cardiovascular risk reduction at the population level and provide additive BP benefit when used alongside conventional therapies. Among individuals with hypertension, GLP-1 RAs are generally well tolerated, although small increases in heart rate and potential interactions with volume-regulating medications may warrant clinical attention. This review the synthesizes current evidence on the mechanisms by which GLP-1 RAs affect BP, their clinical effects across populations, and the implications for patient care. We discuss subpopulations who may benefit from their BP-lowering effects, identify limitations in the existing evidence, and explore future directions for research. As newer GLP-based therapies continue to emerge, a clearer understanding of their effects on BP may inform more integrated approaches to cardiometabolic care.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

The authors have no conflicts of interest to disclose.

PubMed

How GLP-1 Medications Affect Blood Pressure

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief